Argenx reports first quarter 2025 financial results and provides business update

$790 million in first quarter global product net sales first patients treated with vyvgart hytrulo pre-filled syringe for self-injection in us and germany cidp global expansion with positive chmp opinion for vyvgart-sc (vial and pre-filled syringe) in eu management to host conference call today at 2:30 pm cet (8:30 am et) may 8, 2025, 7:00 am cet amsterdam, the netherlands – argenx se (euronext & nasdaq: argx), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its first quarter 2025 financial results and provided a business update. “we continue to execute on our bold innovation agenda, guided by our ‘vision 2030' to reach 50,000 patients across 10 labeled indications,” said tim van hauwermeiren, chief executive officer of argenx.
ARGX Ratings Summary
ARGX Quant Ranking